

Afibercept (EYLEA®) 1 mg

Medicare Part B Coding for Ophthalmic Use

Updated November 2016

Carriers Subject to Change – www.aao.org/coding
The following MACs do not have a policy for EYLEA®: Cahaba, CGS, FSCO, Noridian

Medicare Carrier Part B	CPT & HCPCS Codes	Units	Diagnosis Coverage	Instructions
National Government Services www.ngsmedicare.com JK: Connecticut, Maine, Massachusetts, New Hampshire, New York, Rhode Island, Vermont J6: Illinois, Minnesota, Wisconsin L33394 A52451	67028 J0178	2	E08.311 Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema E08.3211 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye E08.3212 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye E08.3213 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral E08.3311 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye E08.3312 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye E08.3312 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy	Indications: Aflibercept Diabetic macular edema (DME) (Effective July 29, 2014 based on (FDA) approval) Diabetic retinopathy (DR) in patients with DME (Effective March 25, 2015 based on (FDA) approval) Macular edema following retinal vein occlusion (RVO) (Effective October 6, 2014 based on (FDA) approval) Neovascular (wet) age related macular degeneration. The appropriate site modifier (RT, LT or 50) must be appended to CPT code 67028 to indicate if the service was performed unilaterally or bilaterally. Claims without a modifier will be returned to the provider unprocessed

with macular edema, left eve E08.3313 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E08.3411 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eve E08.3412 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye E08.3413 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral E08.3511 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye E08.3512 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema. left eve E08.3513 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral E08.3521 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eve E08.3522 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the

macula, left eye E08.3523 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral E08.3531 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye E08.3532 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye E08.3533 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral E08.3541 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eve E08.3542 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eve E08.3543 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rheamatogenous retinal detachment. bilateral E08.3551 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye

E08.3552 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left E08.3553 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral E08.3591 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eve E08.3592 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye E08.3593 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral E09.311 Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema E09.3211 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eve E09.3212 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eve E09.3213 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E09.3311 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with

macular edema, right eye E09.3312 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye E09.3313 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E09.3411 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye E09.3412 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye E09.3413 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E09.3511 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye E09.3512 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E09.3513 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema. bilateral E09.3521 Drug or chemical induced diabetes mellitus with proliferative

diabetic retinopathy with traction retinal detachment involving the macula, right eye E09.3522 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left E09.3523 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral E09.3531 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eve E09.3532 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eve E09.3533 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral E09.3541 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye E09.3542 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined

traction retinal detachment and rhegmatogenous retinal detachment, left eye E09.3543 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral E09.3551 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy. right eye E09.3552 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eve E09.3553 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy. bilateral E09.3591 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eve E09.3592 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eve E09.3593 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema E10.3211 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right E10.3212 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left

E10.3213 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E10.3311 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eve E10.3312 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eve E10.3313 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E10.3411 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye E10.3412 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eve E10.3413 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E10.3511 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye E10.3512 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E10.3513 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral E10.3521 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eve E10.3522 Type 1 diabetes mellitus with

proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye E10.3523 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral E10.3531 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye E10.3532 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye E10.3533 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral E10.3541 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye E10.3542 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eve E10.3543 Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rheamatogenous retinal detachment, bilateral E10.3551 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eve E10.3552 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye E10.3553 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral

E10.3591 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye E10.3592 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye E10.3593 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema E11.3211 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye E11.3212 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eve E11.3213 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E11.3311 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye E11.3312 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eve E11.3313 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E11.3411 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right E11.3412 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left

E11.3413 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E11.3511 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye E11.3512 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E11.3513 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral E11.3521Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye E11.3522 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye E11.3523 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral E11.3531 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eve E11.3532 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eve E11.3533 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral E11.3541 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eve

E11.3542 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye E11.3543 Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye E11.3552 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye E11.3553 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema. left eve E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral E13.311 Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema E13.3211 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye E13.3212 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eve E13.3213 Other specified diabetes mellitus with mild nonproliferative

diabetic retinopathy with macular edema, bilateral E13.3311 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye E13.3312 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye E13.3313 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E13.3411 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye E13.3412 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye E13.3413 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E13.3511 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right E13.3512 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eve E13.3513 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral E13.3521 Other specified diabetes

mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye E13.3522 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eve E13.3523 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral E13.3531 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eve E13.3532 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eve E13.3533 Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral E13.3541 Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye E13.3542Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye E13.3543 Other specified diabetes mellitus with proliferative diabetic

retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral E13.3551 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye E13.3552 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye E13.3553 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral E13.3591 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye E13.3592 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eve E13.3593 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral H34.8110 Central retinal vein occlusion. right eye, with macular edema H34.8111 Central retinal vein occlusion, right eye, with retinal neovascularization H34.8112 Central retinal vein occlusion. right eye, stable H34.8120 Central retinal vein occlusion, left eye, with macular edema H34.8121 Central retinal vein occlusion. left eye, with retinal neovascularization H34.8122 Central retinal vein occlusion, left eye, stable H34.8130 Central retinal vein

occlusion, bilateral, with macular edema H34.8131 Central retinal vein occlusion. bilateral, with retinal neovascularization H34.8132 Central retinal vein occlusion, bilateral, stable H34.8310 Tributary (branch) retinal vein occlusion, right eye, with macular edema H34.8311 Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization H34.8312 Tributary (branch) retinal vein occlusion, right eye, stable H34.8320 Tributary (branch) retinal vein occlusion, left eye, with macular edema H34.8321 Tributary (branch) retinal vein occlusion. left eve. with retinal neovascularization H34.8322 Tributary (branch) retinal vein occlusion, left eye, stable H34.8330 Tributary (branch) retinal vein occlusion, bilateral, with macular edema H34.8331 Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization H34.8332 Tributary (branch) retinal vein occlusion, bilateral, stable H35.3210 Exudative age-related macular degeneration, right eye, stage unspecified H35.3211 Exudative age-related macular degeneration, right eye, with active choroidal neovascularization H35.3212 Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization H35.3213 Exudative age-related macular degeneration, right eye, with inactive scar

			H35.3220 Exudative age-related macular degeneration, left eye, stage unspecified H35.3221 Exudative age-related macular degeneration, left eye, with active choroidal neovascularization H35.3222 Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization H35.3223 Exudative age-related macular degeneration, left eye, with inactive scar H35.3230 Exudative age-related macular degeneration, bilateral, stage unspecified H35.3231 Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization H35.3232 Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization H35.3233 Exudative age-related macular degeneration, bilateral, with inactive scar H35.351 Cystoid macular degeneration, right eye H35.352 Cystoid macular degeneration, left eye H35.353 Cystoid macular degeneration, bilateral H35.81 Retinal edema	
Novitas Solutions, Inc. www.novitas-solutions.com JH: Arkansas, Colorado, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas JL: Delaware, District of Columbia, Maryland, New Jersey, and Pennsylvania	67028 J0178	2	None listed It is the provider's responsibility to select diagnosis codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.	Providers should bill CPT code 67028 for the intravitreal injections, in addition to the drug(s) utilized. The appropriate site modifier (RT, LT, or 50) must be appended to CPT code 67028 to indicate if the service was performed unilaterally (RT or LT) or bilaterally (50). When billing in the non-outpatient hospital setting; not including the ASC setting:

A53121				 For aflibercept, providers should use the HCPCS code J0178 (Injection, aflibercept, 1 mg), and bill for the proper number of units. For Part B, the actual number of mg utilized should be noted in Item 19 of the CMS Form 1500 or its electronic equivalent. When billing in the hospital outpatient setting and the ASC setting: For aflibercept, providers should use the HCPCS code J0178 (Injection, aflibercept, 1 mg), and bill for the proper number of units. For Part A, the correct number of units should be billed for the dose that is administered in field locator 46 of the UB-92 (CMS Form 1450) along with the revenue code 0636 (Drugs requiring specific identification-detailed coding) in field locator 42.
Palmetto GBA www.palmettogba.com North Carolina, South Carolina, Virginia, West Virginia A53387	67028 J0178	2	Not listed	Effective November 18, 2011, September 21, 2012, July 29, 2014, October 6, 2014 and March 25, 2015 respectively, Aflibercept (Eylea*) was approved by the Food and Drug Administration (FDA) for the treatment of patients with: Neovascular (Wet) Aged-related Macular Degeneration (AMD) Macular Edema following Retinal Vein Occlusion (RVO) Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) in patients with Diabetic Macular Edema (DME) For AMD the recommended dose is 2 mg (0.05 mL) administered by intravitreal injection every four weeks for the first 12 weeks, followed by 2 mg (0.05 ml) once every eight weeks (2 months) by intravitreal injection. For Macular Edema following RVO the recommended dose is 2 mg (0.05 mL) administered

www.wpsmedcarce/index/shtml For DME the recommended dose is 2 mg (0.05 ml) once every 4 weeks for the first 5 injections, and then 2mg (0.05ml) every 2 months (8 weeks) by intravitreal injection once every 4 weeks for the first 5 injections, and then 2mg (0.05ml) every 2 months (8 weeks) by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by intravitreal injection once every 4 methods and injection to every 1 mg (0.05ml) administered by intravitreal injection once every 4 methods and injection once servery 4 weeks initially for the first 5 injections every 4 methods and intraviteral injection once 4 methods and intraviteral injection once 4 methods and intraviteral					
once every 4 weeks for the first 5 injections, and then 2mg (0.05ml) every 2 months (8 weeks) by intravitreal injection. For DR with DME the recommended dose is 2 mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection or every 2 months (8 weeks). To bill affibercept services, submit the following claim information on CMS Form 1500: • J0178 - Infravitreal injection of a pharmacologic agent (separate procedure) Note: Quantity to be billed 67028 is 1 as this is a bilateral procedure. Note: It is not reasonable and necessary to inject more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranbizumab, aflibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the same treatment sension. It is not typical to inject one anti-VEGF medication in one eye and another in the same treatment readications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Documentation scalurements The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "midcations and Limitations of Coverage.") This documentation includes, but in the limited to,					
(.0.05 ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by intravitreal injection every 2 months (8 weeks). To bill afilibercept services, submit the following claim information on CMS Form 1500: • .J0178 - Injection, afilibercept, 1 mg • 67028 - Intravitreal injection of a pharmacologic agent (separate procedure) Note: Quantity to be billed 67028 is 1 as this is a bilateral procedure. Note: It is not reasonable and necessary to inject more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, afilibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Wisconsin Physician Service WPS Wisconsin Physician Service WPS J0178 E08.3212 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye E08.3212 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye E08.3212 Diabetes mellitus due to underlying condition included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to,					once every 4 weeks for the first 5 injections, and then 2mg (0.05ml) every 2 months (8 weeks) by
claim information on CMS Form 1500: JO178 - Injection, aflibercept, 1 mg 67028 - Intravitreal injection of a pharmacologic agent (separate procedure) Note: It is not reasonable and necessary to inject more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, aflibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Wisconsin Physician Service WPS Www.wpsmedcare/index/shtml Wisconsin Physician Service WPS JO178 E08.3211 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with mild nonproliferative diabetic retinopathy with macular edema, right eye E08.3212 Diabetes mellitus due to documentation includes, but is not limited to,					(0.05 ml) administered by intravitreal injection once every 4 weeks initially for the first 5 injections, followed by 2mg (0.05ml) administered by
• 67028 - Intravitreal injection of a pharmacologic agent (separate procedure) Note: Quantity to be billed 67028 is 1 as this is a bilateral procedure. Note: It is not reasonable and necessary to inject more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, aflibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Wisconsin Physician Service WPS Www.wpsmedcare/index/shtml EO8.3211 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye EO8.3212 Diabetes mellitus due to documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to,					
bilateral procedure. Note: It is not reasonable and necessary to inject more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, afilibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Wisconsin Physician Service WPS JO178 Www.wpsmedcare/index/shtml Bilateral procedure. Note: It is not reasonable and necessary to inject more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, afilibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Documentations Requirements The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to,					67028 - Intravitreal injection of a pharmacologic
more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, aflibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug. Wisconsin Physician Service WPS J0178 E08.3211 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with mild nonproliferative diabetic retinopathy with meacular edema, right eye E08.3212 Diabetes mellitus due to Www.wpsmedcare/index/shtml E08.3212 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with mecasity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to,					
Wisconsin Physician Service WPS JO178 Www.wpsmedcare/index/shtml Westerm 1					more than one anti-vascular endothelial growth factor (VEGF) medication (bevacizumab, ranibizumab, aflibercept) in the same eye during the same treatment session. It is not typical to inject one anti-VEGF medication in one eye and another in the other eye. If different medications are injected into each eye during the same DOS, the rationale for this therapy must be documented in the medical record and the billing modifier (RT/LT) must be appended to the correct drug.
www.wpsmedcare/index/shtml J0178 nonproliferative diabetic retinopathy with necessity for services included within this LCD. (See macular edema, right eye macular edema, right eye E08.3212 Diabetes mellitus due to documentation includes, but is not limited to,	Wisconsin Physician Service	67028	2		
www.wpsmedcare/index/shtml macular edema, right eye "Indications and Limitations of Coverage.") This documentation includes, but is not limited to,			2	nonproliferative diabetic retinopathy	documentation that fully supports the medical
	www.wpsmedcare/index/shtml	J01/8		macular edema, right eye	"Indications and Limitations of Coverage.") This
	J8: Iowa, Kansas, Missouri, and			E08.3212 Diabetes mellitus due to underlying condition with mild	documentation includes, but is not limited to, relevant medical history, physical examination, and

Nebraska nonproliferative diabetic retinopathy with J5: Indiana, Michigan macular edema, left eye E08.3213 Diabetes mellitus due to underlying condition with mild L34741 nonproliferative diabetic retinopathy with macular edema, bilateral E08.3311 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye E08.3312 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye E08.3313 Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E08.3411 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eve E08.3412 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema. left eve E08.3413 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral E08.3511 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular

edema, right eye

edema, left eye

E08.3512 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular

results of pertinent diagnostic tests or procedures. The medical record must include the following information:

- A physician's order
- The name of the drug or biological administered:
- The route of administration:
- The dosage (e.g., mgs, mcgs, cc's or IU's);
- The duration of the administration- start and stop time must be documented for IV infusions.
- When a portion of the drug or biological is discarded, the medical record must clearly document the amount administered and the amount wasted or discarded.

Utilization Guidelines

Injections of drugs that are administered at an excessive frequency are not medically necessary. Frequency is considered excessive when services are performed more frequently than listed in the package insert or generally accepted by peers and the reason for additional services

When billing an intravitreal injection of a pharmacologic agent; eg, Lucentis (Ranibizumab), Eylea (Aflibercept), or Avastin (Bevacizumab) use HCPCS code 67028 Intravitreal injection of a pharmacologic agent (separate procedure) and the appropriate modifier: RT, LT or 50 (bilateral).

E08.3513 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral E09.3211 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye E09.3212 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye E09.3213 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E09.3311 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye E09.3312 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye E09.3313 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E09.3411 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye E09.3412 Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye E09.3413 Drug or chemical induced diabetes mellitus with severe

nonproliferative diabetic retinopathy with macular edema, bilateral E09.3511 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye E09.3512 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E09.3513 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral E10.3211 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eve E10.3212 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eve E10.3213 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E10.3311 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema. right eye E10.3312 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye E10.3313 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E10.3411 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E10.3412 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left E10.3413 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E10.3511 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye E10.3512 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E10.3513 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral E11.3211 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye E11.3212 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eve E11.3213 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E11.3311 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, riaht eve E11.3312 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eve E11.3313 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E11.3411 Type 2 diabetes mellitus with severe nonproliferative diabetic

retinopathy with macular edema, right eve E11.3412 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eve E11.3413 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E11.3511 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye E11.3512 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E11.3513 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral E13.3211 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye E13.3212 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye E13.3213 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral E13.3311 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eve E13.3312 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eve E13.3313 Other specified diabetes

mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral E13.3411 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye E13.3412 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eve E13.3413 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral E13.3511 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eve E13.3512 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye E13.3513 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral H35.051 Retinal neovascularization, unspecified, right eve H35.052 Retinal neovascularization, unspecified, left eye H35.053 Retinal neovascularization, unspecified, bilateral H35.3210 Exudative age-related macular degeneration, right eye, stage unspecified H35.3211 Exudative age-related macular degeneration, right eye, with active choroidal neovascularization H35.3212 Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization

H35.3213 Exudative age-related macular degeneration, right eye, with inactive scar H35.3220 Exudative age-related macular degeneration, left eye, stage unspecified H35.3221 Exudative age-related macular degeneration, left eye, with active choroidal neovascularization H35.3222 Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization H35.3223 Exudative age-related macular degeneration, left eye, with inactive scar H35.3230 Exudative age-related macular degeneration, bilateral, stage unspecified H35.3231 Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization H35.3232 Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization H35.3233 Exudative age-related macular degeneration, bilateral, with inactive scar H34.8110 Central retinal vein occlusion. right eye, with macular edema H34.8111 Central retinal vein occlusion, right eye, with retinal neovascularization H34.8112 Central retinal vein occlusion. right eye, stable H34.8120 Central retinal vein occlusion, left eye, with macular edema H34.8121 Central retinal vein occlusion. left eye, with retinal neovascularization H34.8122 Central retinal vein occlusion, left eye, stable H34.8130 Central retinal vein

occlusion, bilateral, with macular edema H34.8131 Central retinal vein occlusion, bilateral, with retinal neovascularization H34.8132 Central retinal vein occlusion, bilateral, stable H34.8310 Tributary (branch) retinal vein occlusion, right eye, with macular edema H34.8311 Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization H34.8312 Tributary (branch) retinal vein occlusion, right eye, stable Macular Edema following retinal vein occlusion (RVO). Code macular edema H35.81 and H34.811-H34.813 -Central retinal vein occlusion (CRVO) or H34.831-H34.833-Venous tributary branch occlusion (BRVO) H34.8320 Tributary (branch) retinal vein occlusion, left eye, with macular edema H34.8321 Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization H34.8322 Tributary (branch) retinal vein occlusion, left eye, stable H34.8330 Tributary (branch) retinal vein occlusion, bilateral, with macular edema H34.8331 Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization H34.8332 Tributary (branch) retinal vein occlusion, bilateral, stable

H35.81 Retinal edema